Panacea and Uruguay's Clausen link up for immunosuppressants
This article was originally published in Scrip
Executive Summary
Panacea Biotec, India's third-largest biotech firm by revenues, has entered into an agreement with Laboratorios Clausen of Uruguay under which the latter will market Panacea's Pangraf (tacrolimus) in certain markets in Europe.